REFERENCES
1. Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7:851-61.
2. Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global burden of liver disease: 2023 update. J Hepatol. 2023;79:516-37.
3. Lazarus JV, Mark HE, Villota-Rivas M, et al; NAFLD policy review collaborators. The global NAFLD policy review and preparedness index: are countries ready to address this silent public health challenge? J Hepatol. 2022;76:771-80.
4. Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70:151-71.
5. Flemming JA, Djerboua M, Groome PA, Booth CM, Terrault NA. NAFLD and alcohol-associated liver disease will be responsible for almost all new diagnoses of cirrhosis in Canada by 2040. Hepatology. 2021;74:3330-44.
6. He Y, Su Y, Duan C, et al. Emerging role of aging in the progression of NAFLD to HCC. Ageing Res Rev. 2023;84:101833.
7. Wynne HA, Cope LH, Mutch E, Rawlins MD, Woodhouse KW, James OF. The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology. 1989;9:297-301.
8. Wang J, Zhang W, Liu X, Kim M, Zhang K, Tsai RYL. Epigenome-wide analysis of aging effects on liver regeneration. BMC Biol. 2023;21:30.
9. Hamczyk MR, Nevado RM, Barettino A, Fuster V, Andrés V. Biological versus chronological aging: JACC focus seminar. J Am Coll Cardiol. 2020;75:919-30.
11. Nie C, Li Y, Li R, et al. Distinct biological ages of organs and systems identified from a multi-omics study. Cell Rep. 2022;38:110459.
12. Diebel LWM, Rockwood K. Determination of biological age: geriatric assessment vs biological biomarkers. Curr Oncol Rep. 2021;23:104.
13. Schneider CV, Schneider KM, Teumer A, et al. Association of telomere length with risk of disease and mortality. JAMA Intern Med. 2022;182:291-300.
14. Loomba R, Gindin Y, Jiang Z, et al. DNA methylation signatures reflect aging in patients with nonalcoholic steatohepatitis. JCI Insight. 2018;3:96685.
15. Sudlow C, Gallacher J, Allen N, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12:e1001779.
16. Bedogni G, Bellentani S, Miglioli L, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33.
17. Ho B, Thompson A, Jorgensen AL, Pirmohamed M. Role of fatty liver index in risk-stratifying comorbid disease outcomes in non-alcoholic fatty liver disease. JHEP Rep. 2023;5:100896.
18. Hong S, Hao Y, Sun L, et al. Prevalence and risk factors of significant fibrosis in chronic hepatitis B patients with concurrent metabolic dysfunction-associated steatotic liver disease. Ann Hepatol. 2025;30:101589.
19. Emdin CA, Haas M, Ajmera V, et al. Association of genetic variation with cirrhosis: a multi-trait genome-wide association and gene-environment interaction study. Gastroenterology. 2021;160:1620-33.e13.
20. Nagelkerke NJD. A note on a general definition of the coefficient of determination. Biometrika. 1991;78:691-2.
21. Klemera P, Doubal S. A new approach to the concept and computation of biological age. Mech Ageing Dev. 2006;127:240-8.
22. Levine ME. Modeling the rate of senescence: can estimated biological age predict mortality more accurately than chronological age? J Gerontol A Biol Sci Med Sci. 2013;68:667-74.
23. Levine ME, Lu AT, Quach A, et al. An epigenetic biomarker of aging for lifespan and healthspan. Aging. 2018;10:573-91.
24. Belsky DW, Caspi A, Arseneault L, et al. Quantification of the pace of biological aging in humans through a blood test, the DunedinPoAm DNA methylation algorithm. Elife. 2020;9:e54870.
25. Kwon D, Belsky DW. A toolkit for quantification of biological age from blood chemistry and organ function test data: BioAge. Geroscience. 2021;43:2795-808.
26. McEwen LM, Jones MJ, Lin DTS, et al. Systematic evaluation of DNA methylation age estimation with common preprocessing methods and the Infinium MethylationEPIC BeadChip array. Clin Epigenetics. 2018;10:123.
28. Mather KA, Jorm AF, Parslow RA, Christensen H. Is telomere length a biomarker of aging? A review. J Gerontol A Biol Sci Med Sci. 2011;66:202-13.
29. Hastings WJ, Shalev I, Belsky DW. Comparability of biological aging measures in the National Health and Nutrition Examination Study, 1999-2002. Psychoneuroendocrinology. 2019;106:171-8.
30. Parker DC, Bartlett BN, Cohen HJ, et al. Association of blood chemistry quantifications of biological aging with disability and mortality in older adults. J Gerontol A Biol Sci Med Sci. 2020;75:1671-9.
31. Bassett DR Jr. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003;35:1396.
32. Li R, Chambless L. Test for additive interaction in proportional hazards models. Ann Epidemiol. 2007;17:227-36.
33. Assmann SF, Hosmer DW, Lemeshow S, Mundt KA. Confidence intervals for measures of interaction. Epidemiology. 1996;7:286-90.
34. Tian T, Zeng J, Meng SY, et al. Accelerated biological aging, genetic susceptibility, and incident severe MASLD, liver cirrhosis and cancer. 2024.
35. Xia M, Li W, Lin H, et al. DNA methylation age acceleration contributes to the development and prediction of non-alcoholic fatty liver disease. Geroscience. 2024;46:3525-42.
36. Tang L, Li D, Ma Y, Cui F, Wang J, Tian Y. The association between telomere length and non-alcoholic fatty liver disease: a prospective study. BMC Med. 2023;21:427.
37. Papatheodoridi AM, Chrysavgis L, Koutsilieris M, Chatzigeorgiou A. The role of senescence in the development of nonalcoholic fatty liver disease and progression to nonalcoholic steatohepatitis. Hepatology. 2020;71:363-74.
38. Dabravolski SA, Bezsonov EE, Orekhov AN. The role of mitochondria dysfunction and hepatic senescence in NAFLD development and progression. Biomed Pharmacother. 2021;142:112041.
39. Kim IH, Xu J, Liu X, et al. Aging increases the susceptibility of hepatic inflammation, liver fibrosis and aging in response to high-fat diet in mice. Age. 2016;38:291-302.
40. Du K, Umbaugh DS, Ren N, Diehl AM. Cellular senescence in liver diseases: from molecular drivers to therapeutic targeting. J Hepatol. 2025;Epub ahead of print.
41. Chen L, Wu B, Mo L, et al. High-content screening identifies ganoderic acid A as a senotherapeutic to prevent cellular senescence and extend healthspan in preclinical models. Nat Commun. 2025;16:2878.
42. Tang W, Zhang Q, Qin L, et al. M6PR upregulation by berberine attenuates hepatic senescence via sorting STING into endosome for degradation. Phytomedicine. 2025;145:157089.
43. Zhao Y, Gao L, Chen J, et al. Remote limb ischemic conditioning alleviates steatohepatitis via extracellular vesicle-mediated muscle-liver crosstalk. Cell Metab. 2025;37:886-902.e7.
44. Saenz E, Montagut NE, Wang B, et al. Manipulating the gut microbiome to alleviate steatotic liver disease: current progress and challenges. Engineering. 2024;40:51-60.
45. Tincopa MA, Anstee QM, Loomba R. New and emerging treatments for metabolic dysfunction-associated steatohepatitis. Cell Metab. 2024;36:1430.
46. Ruhl CE, Everhart JE. Fatty liver indices in the multiethnic United States National Health and Nutrition Examination Survey. Aliment Pharmacol Ther. 2015;41:65-76.
